Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Return on Sales (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Return on Sales for 3 consecutive years, with 15.14% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Return on Sales rose 1438.0% year-over-year to 15.14%, compared with a TTM value of 15.14% through Dec 2024, up 1438.0%, and an annual FY2024 reading of 19.72%, up 1592.0% over the prior year.
  • Return on Sales was 15.14% for Q4 2024 at Oramed Pharmaceuticals, up from 5.15% in the prior quarter.
  • Across five years, Return on Sales topped out at 15.14% in Q4 2024 and bottomed at 35.26% in Q2 2024.
  • Average Return on Sales over 3 years is 9.14%, with a median of 9.23% recorded in 2023.
  • The sharpest move saw Return on Sales skyrocketed 1439bps in 2023, then tumbled -2964bps in 2024.
  • Year by year, Return on Sales stood at 13.63% in 2022, then soared by 106bps to 0.76% in 2023, then soared by 1903bps to 15.14% in 2024.
  • Business Quant data shows Return on Sales for ORMP at 15.14% in Q4 2024, 5.15% in Q3 2024, and 35.26% in Q2 2024.